Recombinant Human IL-21R His-tag Protein, CF

Measured by its ability to inhibit IL-21-dependent enhancement of IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED50 for this effect is 15-150 ng/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-21R His-tag Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit IL-21-dependent enhancement of IFN-gamma secretion in NK-92 human natural killer lymphoma cells. The ED₅₀ for this effect is 15-150 ng/mL.
• Source: Human embryonic kidney cell, HEK293-derived human IL-21R protein
  Cys20-Pro236, with a C-terminal 6-His tag
• Accession #: Q9HBE5
• N-terminal Sequence: Cys20
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 26 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 45-53 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-21R His-tag Protein, CF

• CD360 antigen
• CD360
• IL-21 R
• IL-21 receptor
• IL21R
• IL-21R
• interleukin 21 receptor
• interleukin-21 receptor
• MGC10967
• NILR
• Novel interleukin receptor

Background

Interleukin-21 Receptor (IL-21 R )is a type I transmembrane glycoprotein within the class I cytokine receptor family (1). IL-21 R associates with the common gamma  chain ( gamma _c) which is also a component of the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (2, 3). Mature human IL-21 R consists of a 213 amino acid (aa) extracellular domain (ECD) with 4 conserved cysteine residues, a fibronectin type III domain, and a WSxWS motif, followed by a 21 aa transmembrane domain and a 285 aa cytoplasmic domain with a Box 1 motif, a kinase domain, and several sites for tyrosine phosphorylation (4, 5). Within the ECD, human IL-21 R shares 69% aa identity with mouse and rat IL-21 R, respectively. IL-21 R is expressed mainly on B cells (highest on mature, activated, follicular and germinal center B cells), NK cells, and activated T cells, but is also found on dendritic cells, alternatively activated macrophages, intestinal lamina propria fibroblasts and epithelial cells, and keratinocytes (1, 4, 5). Both IL-21 and IL-4 are necessary for efficient B cell IgG1 production and normal germinal center architecture (6). B cell IL-21 R engagement induces Blimp-1 (which mediates plasma cell differentiation) and is important for memory responses (7, 8). IL-21 R engagement enhances NK cell mediated cytotoxic activity and IFN-gamma production (4, 9), control of viral infection and tumor growth by CD8⁺ T cells (10), development of regulatory T cells (11), IL-23 responsiveness of encephalitogenic Th17 cells (12), but suppresses the accumulation of IL-17 secreting gamma δ T cells in the airway (13). IL-21 R expression is often upregulated in allergic skin inflammation, systemic lupus erythematosus and diffuse large B cell lymphoma (DLBCL) (14, 15).

1. Tangye, S.G. (2015) Curr. Opin. Immunol. 34:107.
2. Asao, H. et al. (2001) J. Immunol. 167:1.
3. Habib, T. et al. (2002) Biochemistry 41:8725.
4. Parrish-Novak, et al. (2000) Nature 408:57.
5. Ozaki, K. et al. (2000) Proc. Natl. Acad. Sci. USA 97:11439.
6. Ozaki, K. et al. (2002) Science 298:1630.
7. Rankin, A.L. et al. (2011) J. Immunol. 186:667.
8. King, I.L. et al. (2010) J. Immunol. 185:6138.
9. Kasaian, M.T. et al. (2002) Immunity 16:559.
10. Frohlich, A. et al. (2009 Science 324:1576.
11. Tortola, L. et al. (2010) Blood 116:5200.
12. Lee, Y. et al. (2015) J. Clin. Invest. 125:4011.
13. Moser, E.K. et al. (2015) PLoS One 10:e0120169.
14. Jin, H. et al. (2009) J. Clin. Invest. 119:47.
15. Sarosiek, K.A. et al. (2010) Blood 115:570.

Publications for IL-21R (9249-R2)(2)

Publications using 9249-R2

• Chun, JH;Lim, BS;Roy, S;Walsh, MJ;Abhiraman, GC;Zhangxu, K;Atajanova, T;Revach, OY;Clark, EC;Li, P;Palin, CA;Khanna, A;Tower, S;Kureshi, R;Hoffman, MT;Sharova, T;Lawless, A;Cohen, S;Boland, GM;Nguyen, T;Peprah, F;Tello, JG;Liu, SY;Kim, CJ;Shin, H;Quijano-Rubio, A;Jude, KM;Gerben, S;Murray, A;Heine, P;DeWitt, M;Ulge, UY;Carter, L;King, NP;Silva, DA;Kueh, HY;Kalia, V;Sarkar, S;Jenkins, RW;Garcia, KC;Leonard, WJ;Dougan, M;Dougan, SK;Baker, D; Potent antitumor activity of a designed interleukin-21 mimic bioRxiv : the preprint server for biology 2024-12-07 [PMID: 39677740] (Bioassay)
• Ferreira-Gomes, M;Chen, Y;Durek, P;Rincon-Arevalo, H;Heinrich, F;Bauer, L;Szelinski, F;Guerra, GM;Stefanski, AL;Niedobitek, A;Wiedemann, A;Bondareva, M;Ritter, J;Lehmann, K;Hardt, S;Hipfl, C;Hein, S;Hildt, E;Matz, M;Mei, HE;Cheng, Q;Dang, VD;Witkowski, M;Lino, AC;Kruglov, A;Melchers, F;Perka, C;Schrezenmeier, EV;Hutloff, A;Radbruch, A;Dörner, T;Mashreghi, MF; Recruitment of plasma cells from IL-21-dependent and IL-21-independent immune reactions to the bone marrow Nature communications 2024-05-17 [PMID: 38755157] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • Q9HBE5()